AbbVie Inc (ABBV)vsTvardi Therapeutics, Inc. (TVRD)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
TVRD
Tvardi Therapeutics, Inc.
$2.95
-6.94%
HEALTHCARE · Cap: $25.42M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 5.8% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TVRD
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for TVRD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : TVRD
The strongest argument for TVRD centers on Debt/Equity, Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : TVRD
The primary concerns for TVRD are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 25/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Tvardi Therapeutics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies for oncology and other significant medical issues. Leveraging its proprietary drug discovery platform, Tvardi specializes in small molecule therapies targeting protein degradation pathways, aiming to enhance treatment efficacy in cancer care. The company’s lead candidate, TVB-2640, disrupts cancer cell survival mechanisms, reflecting its commitment to advancing novel treatment options for patients with malignancies. With a robust pipeline and a focus on scientific excellence, Tvardi is strategically positioned to make a meaningful impact in the cancer therapeutics landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?